Skip to main content

Table 1 Pre-transplant immunology profiles of patients 1 and 2

From: Rapid reduction of high-level pre-formed donor-specific antibodies after simultaneous liver-kidney transplantation: a report of two cases

Patient 1

No. of HLA Mismatches

4/6

 
  

#C1q assay

#DSA (MFI)

B60, DQ2, DQA1*05:02, DQ4 (> 20,000)

Positive

DR8, DR17 (> 10,000)

Negative

DR52, C*07:02 (> 1500)

Negative

CDC Crossmatch

T cell

Positive

 

B cell

Positive

 

cPRA

Class I and Class II 99%

 

Patient 2

No. of HLA Mismatches

6/6

 
  

#C1q assay

#DSA (MFI)

DR52, DR14 (> 10,000)

Negative

DR4, DQ5 (> 3000)

Negative

DQ7 (> 1000)

Positive

CDC Crossmatch

T cell

Negative

 

B cell

Negative

 

cPRA

Class II only 97%

 
  1. (HLA Human leukocyte antigen, DSA Donor-specific antibody, MFI Mean fluorescence intensity, CDC crossmatch Complement-dependent cytotoxic crossmatch, cPRA calculated panel-reactive antibody)
  2. #Sera were tested using LABScreen™ single antigen beads (One Lambda, Canoga Park, CA) with a threshold mean fluorescent intensity ≥500, pre-test dilution was not routinely performed
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us